Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04736199
Title Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications

prostate adenocarcinoma

Therapies

Darolutamide

Age Groups: senior | adult
Covered Countries ESP | CAN


No variant requirements are available.